Is Aristo Bio-Tech overvalued or undervalued?

As of 27 June 2025, the valuation grade for Aristo Bio-Tech has moved from very expensive to expensive. The company is currently considered overvalued. Key ratios include a PE Ratio of 18.87, an EV to EBITDA of 10.45, and a PEG Ratio of 4.60, which indicates a high valuation relative to its earnings growth potential.
In comparison to its peers, Aristo Bio-Tech's PE Ratio is significantly lower than that of P I Industries at 37.95 and Bayer CropScience at 47.99, both classified as very expensive. Additionally, while UPL is rated attractive with a PE of 38.72, Aristo's valuation remains on the higher side within its category. Notably, Aristo's stock has underperformed against the Sensex in the past month and year-to-date, further supporting the view that it is overvalued in the current market context.